Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry

You may also be interested in...

Is The Non-compete Clause For Cross-border Deals In India A Burden Or A Boost?

Deal makers are cautiously viewing the fallout of a recent government statute to prevent non-compete clauses in cross-border deals for existing Indian companies except in special circumstances. Experts await clarification on the statute but some say the new norm will impede deals and affect valuations.

Global Firms Can Now Buy A Controlling Stake In Indian Companies, But The Debate Is Not Over

A truce between government departments was reached on the issue of foreign direct investments in the pharmaceutical industry. In the new setting, the “non-compete” clause will be removed lending flexibility to the seller to start up a competing enterprise.

India Proposes Stricter Rules For Local Buy-Outs By Foreign Firms

A proposal by an Indian government department may make buy-outs of existing local drug units difficult for global companies. The new provisions include removal of a non-compete clause and several other pre-conditions for the buyer.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts